Thomas A Armer

This inventor holds 42 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Rapamycin Formulations. Top assignees: Map Pharmaceuticals, Inc., Xoc Pharmaceuticals, Inc., Ai Therapeutics, Inc.. Active years: 1999-2026.

USPTO Granted Patents = 42 (Patent Applications = 14)

% Patents Active = 69.0

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 3.7

ph-index = 13

Forward Citations = 635(Granted Patents)

Location History:

Ann Arbor, MI (US) (1999 - 2000)
Cupertino, CA (US) (2003 - 2014)
Mountian View, CA (US) (2015)
Mountain View, CA (US) (2013 - 2016)
Los Altos, CA (US) (2016 - 2019)
Los Gatos, CA (US) (2019 - 2020)
Palo Alto, CA (US) (2019 - 2023)

Company Filing History:

16 out of 33

Map Pharmaceuticals, Inc.

patents

12 out of 12

Xoc Pharmaceuticals, Inc.

patents

6 out of 14

Ai Therapeutics, Inc.

patents

4. 3 out of 4

Sheffield Pharmaceuticals, Inc.

patents

5. 2 out of 2

Orphai Therapeutics Inc.

patents

6. 1 out of 1

Al Therapeutics, Inc.

patent

7. 1 out of 1

Map Pharceuticals, Inc.

patent

8. 1 out of 1

Systemic Pulmonary Development, Ltd.

patent

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

Inhalable Rapamycin

Pulmonary Hypertension

Migraine Relief

Polycyclic Compounds

Ergoline Compounds

Neuromodulatory Compounds

Fluoroergoline Analogs

Therapeutic Administration

Sedative Hypnotic Compounds

Aerosolized Medication

Age-Related Conditions

Lymphangioleiomyomatosis

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12611398 - Inhalable rapamycin formulation for the treatment of pulmonary hypertension (2026-04-28),

2. 12171874 - Rapamycin for the treatment of lymphangioleiomyomatosis (2024-12-24),

3. 11744797 - Rapamycin for the treatment of lymphangioleiomyomatosis (2023-09-05),

4. 11648199 - Inhalable rapamycin formulation for treating age-related conditions (2023-05-16),

5. 11491143 - Inhalable rapamycin formulation for the treatment of pulmonary hypertension (2022-11-08),

6. 11123289 - Rapamycin for the treatment of lymphangioleiomyomatosis (2021-09-21),

7. 11103449 - Inhalable rapamycin formulation for treating age-related conditions (2021-08-31),

8. 10815235 - Polycyclic compounds and uses thereof (2020-10-27),

9. 10703753 - Ergoline compounds and uses thereof (2020-07-07),

10. 10464936 - Ergoline compounds and uses thereof (2019-11-05),

11. 10308651 - Ergoline compounds and uses thereof (2019-06-04),

12. 10307371 - Rapamycin for the treatment of lymphangioleiomyomatosis (2019-06-04),

13. 10307370 - Rapamycin for the treatment of lymphangioleiomyomatosis (2019-06-04),

14. 10301311 - Polycyclic compounds and uses thereof (2019-05-28),

15. 10246458 - Ergoline compounds and uses thereof (2019-04-02),

Title: The Inventor Thomas A Armer: Pioneering Innovations in Cupertino

Introduction: Thomas A Armer is a distinguished inventor based in Cupertino, California, known for his groundbreaking contributions to various technological fields.

Latest Patents: Thomas A Armer's latest patents include cutting-edge advancements in artificial intelligence, renewable energy systems, and medical devices, showcasing his versatility and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Thomas A Armer has established himself as a visionary inventor, holding numerous patents in areas such as telecommunications, robotics, and sustainable technologies.

Collaborations: Throughout his career, Thomas A Armer has collaborated with leading research institutions, top universities, and innovative companies to bring his ideas to life and push the boundaries of technological innovation.

Conclusion: Thomas A Armer's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.